China NMPA Encourages Foreign Firms to Move Drug and Device Production Onshore

The signal is less about any single factory and more about where regulatory leverage is being applied: NMPA is tying production location to access, pairing onshoring with cluster policy across four designated regions. For multinational drugmakers and device groups, the calculation shifts from import-and-register toward local manufacturing as a condition of market positioning. The open question is whether incentives alone move capital, or whether registration, procurement and IP treatment get linked to domestic production in ways that make the choice less voluntary.